Harrow (HROW) Competitors

Harrow (NASDAQ:HROW) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation.

Does the media favor HROW or NUVL?

In the previous week, Nuvalent had 12 more articles in the media than Harrow. MarketBeat recorded 14 mentions for Nuvalent and 2 mentions for Harrow. Harrow's average media sentiment score of 1.31 beat Nuvalent's score of 0.40 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	3 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend HROW or NUVL?

Harrow currently has a consensus price target of $63.00, suggesting a potential upside of 77.22%. Nuvalent has a consensus price target of $112.36, suggesting a potential upside of 44.72%. Given Harrow's stronger consensus rating and higher probable upside, research analysts clearly believe Harrow is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nuvalent	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Is HROW or NUVL more profitable?

Nuvalent has a net margin of 0.00% compared to Harrow's net margin of -19.75%. Nuvalent's return on equity of -28.63% beat Harrow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-19.75%	-45.57%	-8.87%
Nuvalent	N/A	-28.63%	-27.15%

Does the MarketBeat Community believe in HROW or NUVL?

Harrow received 46 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.18% of users gave Nuvalent an outperform vote while only 58.55% of users gave Harrow an outperform vote.

Company	Underperform	Outperform
Harrow	Outperform Votes 89 58.55%	Underperform Votes 63 41.45%
Nuvalent	Outperform Votes 43 78.18%	Underperform Votes 12 21.82%

Which has more risk and volatility, HROW or NUVL?

Harrow has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Which has stronger earnings & valuation, HROW or NUVL?

Harrow has higher revenue and earnings than Nuvalent. Harrow is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$130.19M	9.73	-$24.41M	-$0.94	-37.82
Nuvalent	N/A	N/A	-$126.22M	-$3.47	-22.37

Do institutionals & insiders have more ownership in HROW or NUVL?

72.8% of Harrow shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 13.7% of Harrow shares are owned by company insiders. Comparatively, 12.5% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Harrow and Nuvalent tied by winning 9 of the 18 factors compared between the two stocks.